A Randomized Trial of Peginterferon alpha-2a With or Without Ribavirin for HBeAg-Negative Chronic Hepatitis B

Date
2010
Author
Raptopoulou-Gigi, Maria
Akdogan, Meral
Simon, Krzysztof
Ormeci, Necati
Tabak, Fehmi
Janssen, Harry L. A.
Hansen, Bettina E.
van Vuuren, Anneke J.
Verhey, Elke
Zondervan, Pieter E.
Cakaloglu, Yilmaz
Rijckborst, Vincent
ter Borg, Martijn J.
Ferenci, Peter
Metadata
Show full item record
Abstract
OBJECTIVES: Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B patients are at high risk of treatment relapse after any antiviral therapy. Combining peginterferon alpha-2a with ribavirin might improve sustained response rates.
URI
http://hdl.handle.net/20.500.12627/66129
https://doi.org/10.1038/ajg.2010.186
Collections